X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Glenmark Pharma with SHASUN PHARMA - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs SHASUN PHARMA - Comparison Results

GLENMARK PHARMA    Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA SHASUN PHARMA GLENMARK PHARMA/
SHASUN PHARMA
 
P/E (TTM) x 14.7 123.9 11.9% View Chart
P/BV x 3.9 8.5 45.5% View Chart
Dividend Yield % 0.3 0.2 133.4%  

Financials

 GLENMARK PHARMA   SHASUN PHARMA
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-17
SHASUN PHARMA
Mar-14
GLENMARK PHARMA/
SHASUN PHARMA
5-Yr Chart
Click to enlarge
High Rs99394 1,054.1%   
Low Rs72946 1,599.3%   
Sales per share (Unadj.) Rs325.5214.2 152.0%  
Earnings per share (Unadj.) Rs39.35.3 736.4%  
Cash flow per share (Unadj.) Rs48.715.8 307.6%  
Dividends per share (Unadj.) Rs2.001.00 200.0%  
Dividend yield (eoy) %0.21.4 16.2%  
Book value per share (Unadj.) Rs159.253.3 298.5%  
Shares outstanding (eoy) m282.1756.62 498.4%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.60.3 810.6%   
Avg P/E ratio x21.913.1 167.3%  
P/CF ratio (eoy) x17.74.4 400.5%  
Price / Book Value ratio x5.41.3 412.8%  
Dividend payout %5.118.7 27.2%   
Avg Mkt Cap Rs m242,9913,958 6,139.6%   
No. of employees `00013.0NA-   
Total wages/salary Rs m16,4082,164 758.4%   
Avg. sales/employee Rs Th7,083.9NM-  
Avg. wages/employee Rs Th1,265.4NM-  
Avg. net profit/employee Rs Th855.1NM-  
INCOME DATA
Net Sales Rs m91,85712,127 757.5%  
Other income Rs m374229 162.9%   
Total revenues Rs m92,23012,356 746.4%   
Gross profit Rs m20,3671,009 2,018.4%  
Depreciation Rs m2,644594 445.4%   
Interest Rs m2,373415 571.7%   
Profit before tax Rs m15,724230 6,845.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00 0.0%   
Extraordinary Inc (Exp) Rs m-8100-   
Tax Rs m3,827-73 -5,262.4%   
Profit after tax Rs m11,088302 3,669.9%  
Gross profit margin %22.28.3 266.5%  
Effective tax rate %24.3-31.7 -76.9%   
Net profit margin %12.12.5 484.5%  
BALANCE SHEET DATA
Current assets Rs m68,7466,884 998.6%   
Current liabilities Rs m27,0278,456 319.6%   
Net working cap to sales %45.4-13.0 -350.5%  
Current ratio x2.50.8 312.4%  
Inventory Days Days8562 137.9%  
Debtors Days Days96108 88.8%  
Net fixed assets Rs m24,1324,970 485.5%   
Share capital Rs m282113 249.1%   
"Free" reserves Rs m44,6432,875 1,552.9%   
Net worth Rs m44,9253,020 1,487.5%   
Long term debt Rs m45,3631,817 2,496.1%   
Total assets Rs m117,63913,347 881.4%  
Interest coverage x7.61.6 490.9%   
Debt to equity ratio x1.00.6 167.8%  
Sales to assets ratio x0.80.9 85.9%   
Return on assets %11.45.4 212.9%  
Return on equity %24.710.0 246.7%  
Return on capital %19.113.3 143.7%  
Exports to sales %046.4 0.0%   
Imports to sales %014.2 0.0%   
Exports (fob) Rs mNA5,622 0.0%   
Imports (cif) Rs mNA1,728 0.0%   
Fx inflow Rs m56,1525,843 961.1%   
Fx outflow Rs m8,0842,173 372.0%   
Net fx Rs m48,0683,669 1,309.9%   
CASH FLOW
From Operations Rs m6,574398 1,653.5%  
From Investments Rs m-7,124-1,635 435.7%  
From Financial Activity Rs m5,4321,309 415.1%  
Net Cashflow Rs m1,99271 2,798.3%  

Share Holding

Indian Promoters % 48.3 39.2 123.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 6.9 3.6 191.7%  
FIIs % 34.4 17.6 195.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 39.6 26.5%  
Shareholders   56,727 20,750 273.4%  
Pledged promoter(s) holding % 0.0 12.3 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   ALKEM LABORATORIES  PLETHICO PHARMA  WOCKHARDT LTD.  TORRENT PHARMA  FRESENIUS KABI ONCO.  

Compare GLENMARK PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Trade Marginally Higher; IT Sector Up 2.6%(11:30 am)

Stock markets in India are presently trading marginally higher. Sectoral indices are trading on a mixed note with stocks in the IT sector and healthcare sector witnessing maximum buying interest.

Related Views on News

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

More Views on News

Most Popular

Mutual Funds Clearly Tell Us That There is a Bubble in the Stock Market(Vivek Kaul's Diary)

Jan 11, 2018

The maximum amount of money ever has come into equity mutual funds during the current financial year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

'Smart Money' Enters Bitcoin. Will You?(Smart Contrarian)

Jan 17, 2018

As institutional money enters bitcoin, the gains over the last year could just be the tip of the iceberg.

Increasing Divergence Between Bond Yields and Earnings Yield(Chart Of The Day)

Jan 11, 2018

Over the past couple of months, bond yields have risen, but earning yields have fallen, increasing divergence.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Jan 24, 2018 01:21 PM

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 8-QTR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS